enGene reports positive LEGEND trial data, plans detalimogene BLA submission
- enGene Therapeutics (ENGN) Wednesday reported updated results from Cohort 1 of its Phase 2 LEGEND trial evaluating detalimogene in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.
- The company expects the data from 125 patients to form the basis
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.